BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 11, 2005
 |  BioCentury  |  Strategy

Trigen adds at both ends

Trigen Ltd.’s acquisition of ProCorde GmbH in a stock deal, which was to be announced this week, will allow it to integrate upstream while adding a set of preclinical compounds in the same cardiovascular space.

"We wanted to move upstream and were looking for a company targeting synergistic markets," said Sanjay Kakkar, CEO of Trigen (London, U.K.). "With ProCorde, we got biology, preclinical programs, and target discovery and validation platforms for cardiovascular diseases."

Trigen is focused on atheroma and thrombosis and has two core technologies. One is a combinatorial chemistry capability built around amino boronate inhibitors of serine proteases that are specific to coagulation. The other is a protein engineering scaffold containing...

Read the full 548 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >